Sunday June 22nd 18.00-21.00h, Crepperie OY (15 min walk from the venue)
Philips-icometrix Evening Event
Staying Ahead in Neurology: Tracking New Frontiers in MS and Alzheimer´s
Join this evening event and learn how top neurologists are preparing their clinic for the new paradigms in MS and Alzheimer's disease
Join us for an engaging evening hosted by Philips and icometrix on Sunday, June 22, at Crepperie in Helsinki, during the EAN Congress! This event is a unique opportunity to delve into the latest advancements in multiple sclerosis and Alzheimer’s treatments, featuring expert presentations and discussions. Whether you're a healthcare professional, researcher, or simply interested in these critical topics, this evening promises valuable insights and the chance to connect with like-minded individuals. Don’t miss out—register now to secure your spot!
Agenda
Preliminary agenda:
18:00 Walk-in with drinks & bites
18:30 Adapting MS Clinics to the New McDonald Criteria and BTKis - Prof. Friedemann Paul (Charité Berlin, Germany)
19:00 Rolling Out Alzheimer’s Treatments: Monitoring Safety Through Imaging – Prof. Tiago Gil Oliveira (Hospital de Braga, Portugal)
19:30 Networking drink
21:00 Closing
Crepperie
Veturitallinkuja 34, 00520 Helsinki, Finland
Join Us for an Unforgettable Evening!
Book a meeting
Meet with Philips at EAN
Philips is very proud to launch the unique Smart Reading technology, a cloud-based AI toolset that integrates imaging and reading on the MR scanner. Smart Reading drives precision diagnosis to a new level by providing fully automated AI-based quantitative reports for neurological indications like Alzheimer’s and Multiple Sclerosis, in close cooperation with icometrix.
Meet with icometrix at EAN
icometrix transforms brain MRI into actionable insights for clinicians worldwide with AI-powered, MDR-compliant solutions. icobrain ms is the most clinically validated AI solution for multiple sclerosis, delivering standardized, guideline-aligned reports to support ongoing clinical follow-up. icobrain ms+ (research use only) adds advanced quantification of emerging biomarkers, including PRLs and CVS. For Alzheimer’s care, icobrain aria remains the only AI solution that detects, monitors, and grades ARIA—supporting safer anti-amyloid therapy.
